Drug Trial Radar · NCT04264806
A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)
Last checked: Nov 19, 2026Latest source record: May 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 6, 2021
Primary completion
Apr 19, 2022
Study completion Jan 28, 2025
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- argenx
- First posted
- Feb 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare overall response rate (ORR) between treatment groups in participants with higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) who are not eligible for Hematopoietic Stem Cell Transplantation (HSCT).
Conditions
- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
Interventions
AzacitidineDrug
Participants will receive subcutaneous (SC) or intravenous (IV) injection of Azacitidine 75 mg/m\^2.
CusatuzumabDrug
Participants will receive SC or IV injection of Cusatuzumab 20 mg/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 4 years
Locations
73 sites in 11 countries. Site status is shown where the registry gives one.
St Vincents Hospital Sydney
Darlinghurst, Australia
St Vincents Hospital Melbourne
Fitzroy, Australia
Peter MacCallum Cancer Institute
Melbourne, Australia
Royal Perth Hospital
Perth, Australia
Westmead Hospital
Westmead, Australia
Wollongong Hospital
Wollongong, Australia
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Câncer
Curitiba, Brazil
Cepon - Centro De Pesquisas Oncologicas
Florianópolis, Brazil
Liga Norte Riograndense Contra O Cancer
Natal, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Brazil
Instituto do cancer -COR -Hospital Mae de Deus
Porto Alegre, Brazil
Oncoclínicas
Rio de Janeiro, Brazil
Hospital de Base de São José do Rio Preto
São José do Rio Preto, Brazil
Hospital Paulistano
São Paulo, Brazil
Instituto D'Or de Pesquisa e Ensino (IDOR)
São Paulo, Brazil
CHU d'Angers
Angers, France
Hopital Saint Vincent de Paul
Lille, France
CHU de Limoges, Hopital Dupuytren
Limoges, France
Hôpital de La Conception
Marseille, France
CHU de Nice Hopital de l Archet
Nice, France
Hopital Saint-Louis
Paris, France
Hopital Cochin APHP
Paris, France
CHRU Tours Hôpital Bretonneau
Tours, France
CHU de Nancy_ Hôpital Brabois
Vandœuvre-lès-Nancy, France
Universitatsklinikum Carl Gustav Carcus Dresden
Dresden, Germany
Universitätsklinik Freiburg
Freiburg im Breisgau, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Universitatsklinikum Leipzig
Leipzig, Germany
Klinikum rechts der Isar an der Technischen Universität München
München, Germany
Universitaetsklinikum Ulm
Ulm, Germany
Policlinico Sant'Orsola Malpighi
Bologna, Italy
Azienda Ospedaliero Universitaria di Ferrara
Cona, Italy
Università del Piemonte Orientale - Ospedale Maggiore della Carità di Novara
Novara, Italy
Aou San Luigi Gonzaga
Orbassano, Italy
Grande Ospedale Metropolitano 'Bianchi-Melacrino-Morelli' Reggio Calabria
Reggio Calabria, Italy
Fondazione Policlinico Tor Vergata
Roma, Italy
Policlinico Umberto I
Roma, Italy
Istituto Clinico Humanitas
Rozzano, Italy
Emergency Hospital of Dzerzhinsk
Dzerzhinsk, Russia
S.P. Botkin Moscow City Clinical Hospital
Moscow, Russia
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.